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Abstract
Medulloblastoma (MB) is the most common malignant primary pediatric brain tumor. Major research efforts have
focused on characterizing and targeting putative brain tumor stem or propagating cell populations from the tumor
mass. However, less is known about the relationship between these cells and highly invasive MB cells that evade
current therapies. Here, we dissected MB cellular heterogeneity and directly compared invasion and self-renewal.
Analysis of higher versus lower self-renewing tumor spheres and stationary versus migrating adherent MB cells
revealed differential expression of the cell surface markers CD271 [p75 neurotrophin receptor (p75NTR)] and
CD133. Cell sorting demonstrated that CD271 selects for subpopulations with a higher capacity for self-renewal,
whereas CD133 selects for cells exhibiting increased invasion in vitro. CD271 expression is higher in human fetal
cerebellum and primary samples of the Shh MBmolecular variant and lower in the more aggressive, invasive group 3
and 4 subgroups. Global gene expression analysis of higher versus lower self-renewing MB tumor spheres
revealed down-regulation of a cell movement transcription program in the higher self-renewing state and a novel
potential role for axon guidance signaling in MB-propagating cells. We have identified a cell surface signature
based on CD133/CD271 expression that selects for MB cells with a higher self-renewal potential or invasive ca-
pacity in vitro. Our study underscores a previously unappreciated role for CD271 in selecting for MB cell pheno-
types and suggests that successful treatment of pediatric brain tumors requires concomitant targeting of a
spectrum of transitioning self-renewing and highly infiltrative cell subpopulations.
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Introduction
Medulloblastoma (MB) is the most common malignant primary pedi-
atric brain tumor [1,2]. Classified as grade IV embryonal tumors of
the central nervous system by the World Health Organization, MBs
are derived from the neuronal lineage and exhibit dysregulation of
several pathways associated with primitive neuroectoderm develop-
ment including Wnt, Hedgehog, and Notch signaling [1,2]. Follow-
ing surgery and treatment with chemotherapy and radiation, MBs
often recur as a consequence of tumor cell infiltration into normal
tissue and frequent metastasis through the cerebral spinal fluid [1–3].
Despite numerous advances in understanding the molecular basis for
themalignant state and a 5-year survival rate of 60% to 70% [1], children
with MB suffer from permanent cognitive and physical dysfunction
attributed to the impact of toxic therapies on their developing nervous
system [1].
Cancer stem cell theory suggests that a rare subpopulation of cells
exhibit stem cell properties such as self-renewal capacity and multiline-
age differentiation [4,5]. These cancer stem cells or tumor-propagating
cells (TPCs) would ultimately drive tumorigenesis and must be specif-
ically targeted to abrogate malignant progression. Singh et al. demon-
strated that a small subpopulation of brain tumor cells that express
CD133 cell surface marker exhibit enhanced self-renewal capacity
[6,7]. This work firmly established the existence of a “stem cell–like”
phenotype within malignant brain tumors. However, more recent stud-
ies have shown that CD133− and CD133+ cells exhibit self-renewal
capacity, while CD133− cells can generate more aggressive tumors
in vivo [8–12]. Other studies have demonstrated that the cell surface
marker CD15/SSEA1 selects forMBTPCpopulations inmurinemodels
[13,14]. Given the wide expression of CD133 in many tissues, it will be
necessary to break down the heterogeneity within CD133+/− popula-
tions to identify other markers that also select for aggressive phenotypes.
This is further complicated by recent demonstrations that inter-
conversion of cancer cells between various differentiation states enables
reestablishment of cellular equilibrium irrespective of the cell surface
markers used to sort subpopulations [15]. Indeed, sorted cell fractions
are not static andwill inevitably give rise to other phenotypes in response
to appropriate microenvironmental cues.
Most work on malignant brain tumor cell invasion and TPCs has
been mutually exclusive despite the fact that TPCs and invasive cells
share many cellular and molecular features including resistance to
radiation and chemotherapy [16–22]. While some recent studies
have directly addressed the relationship between invasive carcinoma
cells and TPC populations [23,24], the specific relationship between
TPCs and invasion in brain tumors is less concrete. CD133 has typically
been used as a putative brain tumor–propagating cell (BTPC) marker
[7]; however, recent work has shown that CD133− cells display more
aggressive behavior than the CD133+ cells associated with “stem cell”
function [9,12]. Chen et al. demonstrated that amore primitive CD133−
subpopulation of glioblastoma multiforme (GBM) cells gives rise to
both CD133− and CD133+ subsets. Further validating this work is
the finding that GBM stem cell populations selected on the basis of
“side population” or Hoechst 33342 dye exclusion actually exhibit
decreased migration [25]. In contrast, other reports have shown that
invasive and tumormass or “core”GBMcells exhibit self-renewal capac-
ity and stem cell marker expression; however, the stem cell features are
more pronounced in the invasive population [26].
To date, there are no studies directly examining the specific rela-
tionship between BTPCs and the highly invasive subpopulation in
pediatric brain tumor cells. Here, we tested the hypothesis that dis-
section of MB cellular heterogeneity would reveal phenotypic differ-
ences between the highly self-renewing and invasive phenotypes. To
this end, we deconstructed heterogeneous MB cultures and identified
novel functional relationships among cells expressing CD133 and
CD271 using an in vitro model system. Higher self-renewing cells
exhibit a CD271↑, CD133↓ cell surface signature, whereas a highly
motile cell displays CD271↓, CD133↑ phenotype. This was sup-
ported by down-regulation of the cell motility transcription program
in our highly self-renewing tumor spheres in stem cell conditions. Our
study has identified a previously unappreciated role for CD271 in
selecting for MB cell types and suggests that successful treatment of
MB will require targeting of transitioning self-renewing and highly
infiltrative MB subpopulations expressing several phenotypic markers.
Materials and Methods
Cell Culture and Maintenance
Daoy human MB cells (originally derived from a desmoplastic
cerebellar MB) and D283 cells were purchased from the American
Type Culture Collection (ATCC, Rockville, MD). Cells were cultured
in Eagle’s minimum essential media (EMEM) (ATCC) containing
10% FBS (Fisher Scientific, Ottawa, Ontario). Upon reaching con-
fluency, cells were dissociated in Accutase (Invitrogen, Burlington,
Ontario) and passed 1:15. Neural precursors from normal human
embryonic stem cells called hENs and their transformed MB-like de-
rivatives (t-hENs) were cultured as previously described [27]. Briefly,
cells were dissociated for 5 minutes in Accutase and replated onto poly-
L-lysine/laminin–coated plates (BD Biosciences, Mississauga, Ontario) in
neural proliferation media [Dulbecco’s modified Eagle’s medium
(DMEM)/F12 supplementedwith 1%N2 (Gibco, Burlington,Ontario),
1% B27 (Gibco), 20 ng/ml epidermal growth factor (EGF; R&D Sys-
tems, Minneapolis, MN), and 20 ng/ml basic fibroblast growth factor
(bFGF)]. Cells were passed every 5 days with media changes every 3 days.
For subclone expansion, Daoy MB cells were dissociated and resus-
pended in Dulbecco’s phosphate-buffered saline (DPBS; Fisher Scien-
tific) containing 0.5% FBS. A MoFlo XDP (Beckman Coulter, Inc,
Mississauga, Ontario) cell sorter was used to deposit single Daoy cells
into each well of a 96-well plate. These cells were subsequently cultured
inEMEMwith 10%FBS and expanded. Aliquots of 2.5 × 104 cells were
prepared as hanging drops in 20 μl as previously described [28,29].
Hanging drops were incubated for 3 days to form spheroids and then
transferred to collagen type I gels (VWR, Mississauga, Ontario) pre-
pared as previously described [29]. Following collagen gelation at
37°C, embedded spheroids were then overlain with EMEM containing
10%FBS. Spheroidmeasurements were taken at day 0 and invasion was
measured at 72 hours (day 3) using a Zeiss Primo Vert microscope with
micrometer. Individual Daoy subclones were characterized on the basis
of their invasive capacity.
Flow Cytometry Cell Surface Marker Screen
Daoy subclones were dissociated, washed with DPBS, and cultured
as tumor spheres in ultralow attachment plates with DMEM/F12
containing 1% B27, 1% N2, 20 ng/ml EGF, and 20 ng/ml bFGF.
On day 4, tumor spheres were fed by removal and replacement of
1 ml of media. On day 7, Daoy tumor spheres were dissociated,
washed, and resuspended in DPBS containing 0.5% FBS. Cells were
counted using an automated cell counter (Bio-Rad, Mississauga,
Ontario) or hemocytometer. Cells were then stained with one of the
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following antibodies: CD44-FITC, CD30-FITC, CD184-PE, CD26-
FITC, CD271–Alexa Fluor 647, CD133-PE, CD15-APC, or
CD24-PE. All antibodies were obtained from BD Biosciences, with
the exception of CD133 (Miltenyi Biotec, Cambridge, MA). Flow
cytometry was performed on the MoFlo XDP cell sorter and analyzed
using FlowJo software (Tree Star Inc, Ashland, OR).
Daoy Core and Migrating Cell Dissections
DaoyMB cells were prepared as hanging drops as previously described
[28,29]. After 3 days of incubation, resulting spheroids were transferred
into a plate containing EMEMwith 10% FBS. Spheroids were incubated
for 2 days, at which time the “core” was mechanically dissected from the
migrating cells. The dissected cores as well as the remainingmigrating cells
were dissociated separately, resuspended in DPBS with 0.5% FBS, and
stained with antibodies for CD44, CD30, CD184, CD26, CD271,
CD133, CD15, and CD24 for analysis by flow cytometry.
Fluorescence-activated Cell Sorting
Day 7 passage 2 Daoy tumor spheres were pooled, dissociated, and
counted using an automatic cell counter and stained for CD133 and
CD271. Sort samples were also stained with 7AAD viability dye
(Beckman Coulter, Inc). Cells were sorted on the basis of CD133/
CD271 using a MoFlo XDP cell sorter. Analysis of cell sorting was
performed using FlowJo software. Collected cell fractions were
centrifuged and counted for subsequent functional assays.
For tumor sphere assays, aliquots of 2500 cells from each subpopu-
lation were plated in a 24-well low attachment plates in DMEM/F12
containing 1% B27, 1% N2, 20 ng/ml EGF, and 20 ng/ml bFGF.
Cells were incubated for 5 days, after which tumor spheres were
counted. Tumor spheres from each population were then counted
and replated in aliquots of 2500 cells for secondary tumor sphere assays.
For cumulative cell counts, aliquots of 2500 cells from each subpopu-
lation were plated in a 24-well tissue culture plate in EMEM containing
10% FBS. Cells were fed on day 3, and on day 4, they were dissociated
and counted using a hemocytometer to obtain cumulative cell counts.
For invasion assays, aliquots of 1.5 × 104 to 2.5 × 104 of sorted cell
fractions were prepared as hanging drops and embedded in a type I
collagen matrix as described. Measurements were taken on day 0 and
day 3. Images were taken using a Nikon Eclipse TS100 microscope and
Nikon DS-Fi1 Digital Sight camera (Nikon, Mississauga, Ontario).
Intracerebral Transplantations and Histology
The University of Manitoba Animal Care Committee approved all
procedures and protocols. CD271+/CD133−, CD271−/CD133−,
and unsorted Daoy tumor spheres were intracerebrally injected into
non-obese diabetic severe combined immunodeficient (NOD/SCID)
mice as previously described [7,27]. Briefly, mice were anesthetized
with isoflurane and injected in the right frontal lobe with biologic rep-
licates consisting of 2 × 105 CD271+/CD133−, CD271−/CD133−,
and unsorted Daoy tumor spheres. After 7.5 weeks, animals were per-
fused with formalin and the brains were extracted, placed in formalin for
2 to 7 days, embedded in paraffin, and then sectioned (5-μmthickness).
Sections were dewaxed in xylene and rehydrated through a graded series of
alcohol concentrations. Samples were stained with hematoxylin and
eosin. Slides were mounted and imaged using an EVOS xl core micro-
scope (AMG, Seattle, WA). Malignant cell growth was scored, from a
scale of 0 to 3, where 0 = nomalignant cells with certainty, 1 = indicates
rare clusters of malignant cells confined to subarachnoid compartment,
2 = malignant cells in subarachnoid compartment and infiltrating
perivascular spaces, and 3 = features in 2, in addition to tumor nodules
growing in other areas of the brain or cerebellum. For each tumor sam-
ple, two slides containing six to seven brain sections were scored and
averaged to obtain a grade. Slides were assessed by a neuropathologist
who was blinded to cellular identity.
5-Fluorouracil Treatment
Daoy passage 1 tumor spheres were plated in six-well low attach-
ment plates at a cell density of 1 × 105 cells per well, in duplicate.
Concentrations of 0.5, 1.0, and 2.5 μg/ml 5-fluorouracil (5-FU; Sigma,
Oakville, Ontario) as well as a DMSO control were used. Cells were
plated on day 0, and then after 7 days, samples were dissociated and
half were collected for flow cytometry analysis of CD133/CD271 or
viability using the Annexin V Apoptosis Kit (BD Biosciences). The re-
maining samples were replated in fresh neural precursor media or fresh
neural precursor media with various concentrations of 5-FU. Samples
were then collected and analyzed again at day 14.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Core and migrating cell populations were subjected to quantitative
polymerase chain reaction (qPCR) analysis of Otx2, Sox1, βIII tubulin,
EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, and ephrin B2 transcript
levels. Total RNA was extracted using the AllPrep DNA/RNA Mini
Kit (Qiagen, Mississauga, Ontario) according to the manufacturer’s
guidelines. First-strand cDNA was synthesized using the Superscript
III First Strand Synthesis System (Invitrogen). The following PCR con-
ditions were used: 50°C for 2 minutes, 95°C for 2 minutes, and 40 cy-
cles of 95°C for 15 seconds and 60°C for 30 seconds. qPCR was
conducted using Platinum SYBR Green qPCR SuperMix-UDG (Invi-
trogen) or GoTaq qPCRMaster Mix (Fisher Scientific) and performed
on an Mx3000P (Stratagene, Santa Clara, CA) qPCR system. All
values were normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Specific primer sequences for each gene are listed in TableW4.
Global Gene Expression Profiling
Total RNA was isolated from higher versus lower self-renewing
Daoy MB tumor spheres, using the All-in-One Purification Kit
(Norgen Biotek, Thorold, Ontario) according to the manufacturer’s
instructions. RNA amplification and GeneChip 3′ oligonucleotide
microarray hybridization and processing were performed by the London
Regional Genomics Centre (Robarts Research Institute, London,
Ontario) according to the manufacturer’s protocols (Affymetrix, Santa
Clara, CA). N = 3 biologic replicates for the higher versus lower Daoy
MB tumor spheres were analyzed. Ten micrograms of cRNA was
labeled and hybridized to the Affymetrix Human Gene 1.0 ST chips.
Expression signals were scanned on an Affymetrix GeneChip Scanner
and data extraction was performed using Affymetrix AGCC software.
Data normalization and analysis was performed using Dchip software.
Hierarchical clustering using Pearson correlation coefficients was per-
formed on the normalized data. Differentially expressed genes were
analyzed using Ingenuity Pathway Analysis (Redwood City, CA).
Transcripts dysregulated at least two-fold (upregulated or down-
regulated) in the higher versus lower self-renewing Daoy tumor spheres
with a P < .05 were considered significant.
Exon Array Profiling
Affymetrix Human 1.0 exon array profiling was used to examine
expression of CD271 (p75/NTR) in 14 normal cerebellar samples
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(9 fetal and 5 adult) and 111 primary MBs [30]. Expression of
CD271 (p75/NGFR) across all samples is presented in boxplot format
as log2-transformed signal intensity.
Statistical Analysis
All tests were performed using Prism 5 software (GraphPad Software,
La Jolla, CA) or SPSS Statistics (IBM, Armonk, NY). Descriptive sta-
tistics were used to determine significant differences including mean
and SEM along with one-way analyses of variance, independent sample
two-tailed t tests, and Tukey’s test for multiple comparisons. P values
less than .05 were considered significant.
Results
MB Subclones Exhibit Variable Morphology, Invasiveness,
and Self-Renewal Capacity
To evaluate MB cellular heterogeneity, we first derived subclones
from the Daoy MB cell line. Adherent Daoy cultures were dissociated
Figure 1. Subclones derived from Daoy MB cells exhibit morphologic and cellular heterogeneity. (A) Schematic depicting single-cell
derived clonal expansion of Daoy cells after sorting. Expanded clones were cultured as hanging drop aggregates for 3 days and then
placed into three-dimensional type I collagen gels to follow invasion for 72 hours. (B–E) Representative images of monolayer adherent
cultures and hanging drop aggregates from Daoy subclones. Note that some clones exhibited an elongated morphology (B) and others
displayed a rounded or ruffled (C) appearance. Scale bar, 100 μm. When placed in collagen gels, hanging drops from elongated clones
exhibited a higher invasive capacity (D), whereas hanging drops derived from rounded clones typically grew in collagen but only minimally
invaded (E). Scale bar, 250 μm. (F) Invasive capacity of all 21 subclones derived from the parental Daoy MB cell line. Error bars, SEM.
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into a single-cell suspension and single cells were sorted and individ-
ually plates (Figure 1A). A expanded and then cultured aggregate
preparation [29] (Figure 1, A–C ). Aggregate spheroids were im-
planted into collagen gels, and invasion was measured after 72 hours
(Figure 1, A, D, and E ). The 21 subclones exhibited morphologic
heterogeneity with some displaying an elongated appearance
(Figure 1B), while others exhibit a rounded or ruffled morphology
(Figure 1C ). The elongated subclones demonstrated a higher invasive
capacity than the rounded clones (Figure 1, D and E ). In addition,
there was a six-fold invasion difference between the clones exhibiting
the highest and least invasive capacity (Figure 1F ). The most (N = 5
independent subclones) and least (N = 3 independent subclones) in-
vasive subclones were then plated into neural stem cell (NSC) culture
at a concentration of 20,000 cells/well (5 cells/μl) to examine self-
renewal. In bulk culture, tumor spheres derived from the most inva-
sive subclones exhibited a significantly higher self-renewal capacity
when placed in NSC culture, spheres and this passages (Figure 2A).
After invasive subclones began subsequently expanded as adherent
cultures (Figure 2, B and C ). Tumor spheres from the most invasive
subclones did not adhere and continued to maintain their self-renewal
capacity. Together, these results demonstrate that MB cultures exhibit
morphologic and cellular heterogeneity. Although subcloning leads to
independent, phenotypically distinct subcultures of Daoy cells, there
are likely still subpopulations or lineages of cells within each of these
clonally derived lines that could separately account for the self-renewing
and invasive behaviors. To further define these subpopulations, we
must perform expression profiling to determine which cell surface
markers may select for highly self-renewing or invasive phenotypes.
Tumor Spheres Displaying Higher versus Lower Self-Renewal
Capacity Exhibit Differential Expression of CD271
Tumor spheres derived from our MB subclones displayed differ-
ential self-renewal capacity. Therefore, we wanted to test whether
these same tumor spheres also exhibit changes in cell surface marker
expression. Passage 1 tumor spheres from subclones displaying higher
self-renewal (N = 5 independent subclones) versus lower self-renewal
(N = 3 independent subclones) were comparatively screened for the
presence of cell surface markers already known to play a role in neural
lineage specification, BTPCs, and/or tumor cell metastasis (Figure 2,
D–L). Comparative analysis of higher versus lower self-renewing tumor
spheres using flow cytometry revealed significant differential expression
of CD271 (p75NTR; Figure 2I ). CD24 and CD133 also showed dif-
ferential expression; however, the results were not significant (Figure 2,
J and L). Breakdown of higher versus lower self-renewing tumor spheres
into individual subclones revealed that four of five highly self-renewing
subclones tested exhibited elevated levels of CD271, whereas all three
lower self-renewing subclones tested expressed very low levels (Fig-
ure 2M). To assess whether CD271, CD133, and CD24 are enriched
in tumor sphere culture, we examined expression levels in confluent
adherent cultures with 10% FBS relative to passage 1 and passage 2
tumor spheres (Figure 2, N and O). CD271 and CD133 are elevated
following enrichment for the stem cell–like phenotype (Figure 2N ). In
fact, CD271 levels are enriched 77-fold, even higher than the 36-fold
enrichment seen with CD133 (Figure 2N ). In contrast, CD24 exhibits
a rapid decline over subsequent tumor sphere passages (Figure 2O). To
determine whether CD271 and CD133 are also enriched in other MB
cell lines, we examined expression levels in adherent versus tumor sphere
culture from D283 MB cells. Compared to adherent cultures, D283
tumor spheres exhibit a small but significant and consistent increase
inCD271 expression (FigureW1A). Interestingly, CD133 levels declined
following culture of D283 cells as tumor spheres (Figure W1B). We also
examined CD271 and CD133 levels in our recently described trans-
formed neural precursor model of MB [27]. Relative to normal human
embryonic neural precursors (hENs), neoplastic or transformed human
embryonic neural precursors (t-hENs), exhibit a higher self-renewal
capacity in vitro and an MB phenotype in vivo. A comparison of t-hEN
versus hEN cultures revealed a significant increase in CD271 levels in
t-hEN MB–like cells (Figure W1C). CD133 levels exhibited wide var-
iation between trials and overall remain unchanged (Figure W1D).
Together, these results demonstrate that CD133 patterns vary between
cell lines and support recent findings suggesting that CD133 should not
be used as an exclusive marker for selection of BTPCs [8–12]. Interest-
ingly, in the cell lines tested, CD271 is consistently higher in tumor
sphere culture or MB cells with a higher self-renewal capacity. CD271
may therefore play a novel role in selecting for MB TPCs in vitro.
Migrating MB Cells Exhibit Decreased CD271/CD24 and
Increased CD133 Expression
Tumor spheres derived from the higher versus lower self-renewing
MB subclones exhibit differential expression of CD271. These results
may be attributed to the differences in self-renewal between subclones
specifically in tumor sphere culture or may be linked to the differen-
tial invasive capacities of the parental cultures when placed in collagen
gels. It is unclear whether changing the biologic context will also
change the expression patterns of these cell surface markers. To test
the possibility that cell surface markers exhibit differential expression
Figure 2. Self-renewal capacity and expression of CD271 differs in MB tumor sphere subclones. (A) Self-renewal capacity of the most
versus the least invasive derived tumor spheres. In NSC culture, the most invasive subclones gave rise to a higher number of tumor
spheres over two passages indicative of a higher self-renewal capacity. Error bars, SEM; **P< .01; N = 3 independent experiments. (B, C)
Bright-field images of higher (B) versus lower (C) self-renewing tumor spheres after three passages in culture conditions enriching for BTPC
populations. Scale bar, 200 μm. (D) Schematic depicting the procedure used for comparative cell surface marker expression. MB subclones
were placed in NSC culture, and tumor spheres exhibiting higher versus lower self-renewal capacity (SR) were comparatively screened for
the presence of cell surface markers. (E–L) Quantification of cell surface marker screen on the higher versus lower self-renewing (SR) MB
tumor spheres. Error bars, SEM; *P< .05; N = 5 independent “higher self-renewing” subclones,N = 3 independent “lower self-renewing”
subclones. Each subclone was screened between one and four times, and results were pooled. (M) Breakdown of the higher versus lower
self-renewing tumor sphere subclones for CD271. Four of five higher self-renewing subclones expressed CD271, while zero of three lower
self-renewing subclones expressed significant levels of CD271. (N) Daoy parental adherent cultures grown in 10% FBS exhibit low CD271
and CD133 expression by flow cytometry (left panel). Daoy tumor spheres (passage 1, middle panel; passage 2, right panel) grown in BTPC
conditions exhibit an enrichment of CD271 and CD133 expression by flow cytometry relative to adherent cultures. Insets: live cell–only
controls. (O) Down-regulation of CD24 expression following culture of MB adherent cultures in NSC conditions.
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patterns in other biologic assays, we conducted aggregates to separate
the stationary cells (Figure 3, A and B). MB hanging drop aggregates
from the parental Daoy cell line were allowed to adhere to a cell culture
plate surface and individual cells migrated out from the center over a
48-hour period. The aggregate core was mechanically dissected and
both “core” and “migrating” cell populations were dissociated and
subjected to our eight-cell surface marker antibody screen. CD271
was significantly different between core and migrating cell populations.
In these cell conditions, CD24 and CD133 were also significantly dif-
ferent (Figure 3, C–J). Interestingly, CD271/CD24 levels were higher
in the core cell population, whereas CD133 was higher in the migrating
cells (Figure 3, C–J). In addition, we examined transcript levels of neu-
ral lineage markers by qPCR and found that the primitive neuroecto-
derm marker Otx2 was significantly higher in the core cell population,
while Sox1 levels remain unchanged (Figure 3K ). Interestingly, the
more differentiated βIII tubulin was significantly lower in this core pop-
ulation (Figure 3K ). This was supported at the protein level by flow
cytometry studies demonstrating lower βIII tubulin in the core popu-
lation (data not shown). However, nestin levels were not significantly
different (data not shown). Taken together, these results demonstrate
that lower CD271/CD24 and higher CD133 levels “mark” a migrating
MB versus a core cell and that migrating MB cells may represent a
slightly more differentiated state. Differential expression patterns in
the tumor spheres (Figure 2) may therefore reflect changes in self-re-
newal capacity between the MB subclones. These seemingly opposing
results can be explained by the biologic context or cellular conditions
the MB cells are subjected to. Our results point to novel functional re-
lationships among cells expressing CD271, CD24, and CD133. How-
ever, as CD271 was significantly and consistently elevated in higher
self-renewing tumor spheres and CD133 has been widely implicated
in brain tumorigenesis, we chose to further pursue the relationship be-
tween CD271 and CD133 for additional experiments.
CD271 Selects for MB Cells with Increased Self-Renewal while
CD133 Selects for Cells Exhibiting Higher Invasion
From our screening data, we predicted that CD271 and CD133
would mark cells displaying differences in cellular properties. To test
this hypothesis, we used fluorescence-activated cell sorting tumor
spheres based CD271 Figure 4, these experiments, procedure than
D283, hEN, and t-hEN cell lines. Purified subpopulations were then
subjected to tumor sphere assays, cumulative cell counts in adherent
culture, and invasion assays in collagen gels (Figure 4A).
Sorted MB cells from tumor spheres were replated in NSC culture
at a density of 2500 cells/well (2.5 cells/μl) and the number of tumor
spheres was counted after 5 days (Figure 4, C and D). Cell populations
positive for CD271 (CD133−/CD271+ and CD133+/CD271+) gen-
erated a higher number of tumor spheres over passage (Figure 4, C and
D). CD133−/CD271+ cells displayed the highest enrichment of tumor
spheres with a more than three-fold increase in tumor sphere number
from passages 1 to 2. Our results demonstrate that CD271 select for
MB cells with the highest self-renewal capacity in vitro. These data are
consistent with our findings that both CD271 and CD133 are elevated
in stem cell culture (Figure 2N ); however, CD271, with an even higher
enrichment in Daoy cells, may better select for MB-propagating cells
in vitro.
Sorted subpopulations from MB tumor spheres were also sub-
jected to cell count assays. Briefly, 2500 cells from sorted populations
were plated in adherent conditions in media containing 10% FBS,
and cumulative cell counts were taken after 4 days. Our results dem-
onstrate that the CD133−/CD271− population exhibits a significantly
higher number of cells after 4 days (Figure 4E). Interestingly, the other
three subpopulations exhibit a total cell number lower than the starting
cell population, suggesting a possible survival effect in adherent culture.
These results demonstrate that the fractions exhibiting an elevated
capacity for self-renewal are not the same as those with the highest
cumulative cell number overtime.
In contrast to our results for self-renewal, when sorted MB sub-
populations were cultured as hanging drop aggregates and then
placed into collagen gel invasion assays, the CD133+/CD271− sub-
population demonstrated a higher invasive capacity (Figure 4, F and
G ). Invasion was always highest in the MB subpopulations that
exhibit a lower self-renewal capacity. In addition, we noted a distinct
invasion pattern between the CD133+/CD271− and CD133−/
CD271− cells with the former invading as a collective wave of cells,
whereas the latter is characterized by leading elongated cells and a
stream of less invasive cells lagging behind (Figure 4F ). While the
invasion increase in CD133+/CD271− cells was not significantly dif-
ferent from the other subpopulations, it should be noted that we were
often unable to obtain high CD133+ cell numbers and, consequently,
were only able to generate two complete data sets with replicates from
all four subpopulations. However, these trends support our core versus
migrating cell data (Figure 3), where CD271 levels are higher in the
core cells and CD133 expression is elevated in migrating cells. Collec-
tively, our data demonstrate that combinatory expression of CD271
and CD133 enables selection for MB cells displaying variations in
cellular properties.
CD271+ MB Cells Exhibit Chemoresistance at
Low Concentrations
It is well documented that both BTPCs and highly invasive cells
are resistant to conventional therapies such as chemotherapy and radi-
ation [16–22]. However, the majority of these studies were conducted
in GBMmodels, and less is known about the effect of therapeutic treat-
ments on putative MB self-renewing cells. To investigate the effect of
chemotherapeutic agents onMB subpopulations treatedMB tumor days
Figure 5, A and increased apoptosis enrichment of the CD133−/
CD271+ subpopulation at the lowest concentration of 5-FU (Figure 5,
M–Q). After 14 days, the CD133−/CD271+ fraction that exhibits a
higher capacity for self-renewal is nearly doubled (Figure 5Q). At higher
concentrations, the CD133−/CD271+ subpopulation is significantly
decreased but is still present after 14 days (Figure 5, O–Q). These
patterns are also sustained after 21 days of treatment (data not shown).
Taken together, these results demonstrate that chemotherapeutic agents
fail to eliminate the cell population with the highest capacity for self-
renewal and suggest that in our MB model system, the CD133−/
CD271+ may represent a drug-resistant phenotype.
CD133−/CD271+ Cells Exhibit Tumor-Initiating
Capacity In Vivo
We have shown that CD271 has a novel role in selecting for highly
self-renewing MB cells in vitro. We hypothesized that these cells
would also exhibit tumor-initiating capacity in vivo. To test this, we
specifically sorted CD133−/CD271+ and CD133−/CD271− cells from
MB tumor spheres and injected 2 × 105 cells for each subpopulation
(N = 3 CD133−/CD271+ and N = 4 CD133−/CD271−) along with
unsorted cells from MB tumor spheres (N = 4) intracranially into mice.
After 5 weeks (36 ± 1 days), animals injected with CD133−/CD271+
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cells started to exhibit neurologic signs of potential tumor head
(Figure 6A). While unsorted tumor sphere cells also exhibited these
neurologic signs, this was typically delayed. The average time between
injection and neurologic signs was 41 ± 2.5 days for CD133−/CD271−
cells and 44 ± 2 days for unsorted MB tumor sphere cells (Figure 6A).
After 7.5 weeks, mice injected with unsorted MB tumor spheres dis-
played rare clusters of malignant cells typically confined to the sub-
arachnoid space (Figure 6, C and F ). However, mice injected with
Figure 3. Comparative cell surface marker expression from “core” versus “migrating” MB cells reveals differential expression of CD271,
CD133, and CD24. (A, B) Images of an MB hanging drop aggregate before (A) and after (B) manual “core” dissection. Scale bar, 250 μm.
(C–J) Cell surface marker antibody screen on the “core” versus “migrating” cells from MB aggregates 48 hours after attachment. Cell
surfacemarkers were chosen on the basis of their proposed role in neural lineage specification, brain tumor stem cell self-renewal, and tumor
cell invasion. Error bars, SEM; *P< .05; N = 4 and N = 3 independent experiments. (K) qPCR analysis of selected neural stem cell/primitive
neural transcripts and differentiated neuronal markers in “core” versus “migrating” Daoy MB cells. Error bars, SEM; *P < .05.
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CD133−/CD271+ cells displayed the most prominent tumorigenic fea-
tures (Figure 6, B, D, andG ), characterized by a dense mass of malig-
nant cells exhibiting a high nuclear-to-cytoplasmic ratio, abundant
mitotic and apoptotic figures, diffuse infiltration of malignant cells in
the subarachnoid compartment at the base of the brain, and intense
infiltration into the brain along perivascular spaces (Figure 6, B, D,
and G). This was associated with hydrocephalus due to obstructed ce-
rebrospinal fluid flow. Mice injected with CD133−/CD271− cells also
displayed tumorigenic features (Figure 6, B, E , and H ); however, infil-
tration along perivascular spaces was minimal in comparison (Figure 6,
E and H ). Together, these results demonstrate that CD271+ cells ex-
hibit the capacity for tumor initiation in vivo.
The ability of both CD133−/CD271+ and CD133−/CD271− cells
to initiate tumor formation may reflect 1) each individual sorted sub-
population’s capacity for tumor initiation or 2) a subpopulation’s abil-
ity to reestablish heterogeneity and all cell phenotypes following
Figure 4. CD271 selects for cells exhibiting higher self-renewal capacity and CD133 selects for cells demonstrating higher invasion.
(A) Schematic depicting initial two-marker sorting strategy to obtain four subpopulations. (B) Representative dot plot of sorting paradigm
used to select cells based on CD133/CD271 expression. Red squares depict cell populations from all four quadrants to be sorted. (C, D)
Tumor sphere assays for MB subpopulations following FACS. (C) Tumor spheres sorted on CD133/CD271 at the first passage (p1) following
FACS; N = 3 independent experiments. (D) Tumor spheres sorted on CD133/CD271 at the second passage (p2) following FACS. Error bars,
SEM; *P < .05. (E) Average total number of cells/well in adherent culture following FACS. Error bars, SEM; *P < .05, **P < .01; N = 3
independent experiments. (F, G) Invasion assays from subpopulations sorted on CD133/CD271. (F) Representative images of the highly
invasive CD133+/CD271− subpopulation and the less invasive CD133−/CD271− subpopulation after 3 days in collagen gels. Scale bar,
100 μm. (G) Quantification of invasion for each subpopulation after 3 days in collagen following CD133/CD271 sorts. Error bars, SEM;N = 2
independent experiments.
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Figure 5. 5-FU treatment of MB tumor spheres leads to an enrichment of the CD133−/CD271+ subpopulation. (A–H) Representative
images of Daoy MB tumor spheres treated with 0.5, 1.0, and 2.5 μg/ml 5-FU relative to DMSO controls after 7 days (A–D) and 14 days
(E–H). Scale bar, 250 μm. (I–L) Annexin V/7AAD analysis of Daoy MB tumor spheres treated with 0.5, 1.0, and 2.5 μg/ml 5-FU relative to
DMSO controls after 14 days. (M–Q) Quantification of the effect of 5-FU on CD133/CD271 subpopulations after 14 days. (M–P) Rep-
resentative flow cytometry images of CD133/CD271 expression following treatment with DMSO and 0.5, 1.0, and 2.5 μg/ml 5-FU.
(Q) Quantification of the frequency of specific CD133/CD271 subpopulations following treatment with 5-FU. Error bars, SEM; **P < .01,
***P < .001; N = 4 independent experiments.
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intracranial transplantation. To test these hypotheses, we recultured 1
× 104 sorted CD133+/CD271−, CD133−/CD271+, and CD133−/
CD271− cells as tumor spheres and analyzed CD271 and CD133 levels
after 6 days. CD133−/CD271+ cells consistently recapitulated the
distribution of parental tumor sphere culture phenotypes (Figure 6, I–L).
In particular, the >10:1 ratio of CD133−/CD271+ to CD133+/
CD271− cells was maintained. Both CD133+/CD271− and CD133−/
CD271− cells were also able to generate all four subpopulations, albeit
at different ratios with a notable decline in CD271 (Figure 6, I–L).
Together, these results demonstrate that sorted subpopulations reset
phenotypic equilibrium in culture. This reestablishment could lead
to tumor initiation from the different subpopulations in vivo. Our data
support the idea that cell subpopulations can transition between higher
self-renewing and invasive states.
CD271 Levels Are Higher in the Shh MB Molecular Variant
and Fetal Cerebellum and Lowest in the More Aggressive,
Invasive Group 3 and 4 Subgroups
Recent studies have demonstrated that MB is divided into distinct
molecular subtypes [31]. In particular, a Wnt pathway variant, a Shh
pathway variant, and highly aggressive, metastatic group 3 and 4 sub-
groups have been identified [30,31]. On the basis of the expression
patterns of CD271 in vitro, we predicted that CD271 levels would
be higher in the typically less aggressive Shh and Wnt variants relative
to the invasive/metastatic group 3 and 4 subgroups. To test this
hypothesis, we probed for expression of CD271 in an MB data set
derived from exon array profiling of 111 primary MB and 14 normal
human cerebellar samples (9 fetal cerebellum and 5 adult cerebellum).
CD271 expression was significantly higher in fetal cerebellum and the
Shh molecular variant cerebellum (Figure 7A). As and 4 (Figure 7A).
While CD271 expression in the Wnt subgroup was higher than in
groups 3 and 4, the levels were not significantly different. Overall, these
results lend further support to the concept that CD271 levels are lower
in the most invasive/metastatic phenotypes.
Highly Self-Renewing MB Tumor Spheres Exhibit
Down-Regulation of the Cell Motility
Transcription Program
Our screening and sorting results demonstrate CD271↑, CD133↓
in highly self-renewing tumor spheres but CD271↓, CD133↑ in
migrating/invading cells. Even though the higher self-renewing tumor
sphere subclones were derived from adherent cultures exhibiting elevated
invasion in collagen gel assays, it is unclear whether cells in the “stem cell”
or tumor sphere microenvironment exhibit the same capacity for cell
motility. To address this, we conducted global gene expression analysis
on higher versus lower self-renewing MB tumor spheres from indepen-
dent subclones. Affymetrix analysis revealed that a total of 264 transcripts
were significantly and differentially expressed between the higher versus
lower self-renewing MB tumor spheres (Table W1). Eighty-four tran-
scripts were associated with cellular movement, of which 67 (80%) were
downregulated (Figure W2 and Table W2). On the basis of the direc-
tional changes and known function of the associated transcripts, cellular
movement was predicted to be decreased in higher self-renewing tumor
spheres (Table W3). Among the cellular movement transcripts, path-
ways (Table 1). In B signaling pathways, including the receptors
EPHB1, EPHB3, and EPHB6 as well as the ligand ephrin B2 (Table 1).
Figure 6. CD133−/CD271+ cells exhibit tumor-initiating cell capacity in vivo and MB subpopulations can reestablish phenotypic hetero-
geneity following reculture as tumor spheres. (A) Scatterplot depicting time between injections of unsorted or sorted MB tumor sphere
subpopulations and signs of tumor formation including appearance of a domed head caused by hydrocephalus. *P < .05. (B) Semi-
quantitative scoring of Daoy MB tumor samples, based on a scale of 0 to 3, where 0 = no malignant cells, 1 = rare clusters of malignant
cells confined to the subarachnoid space, 2 = malignant cells in subarachnoid compartment and invasion along perivascular spaces, 3 =
features in 2 plus tumor nodules growing in other areas of the brain or cerebellum. (C–H) Infiltration of malignant MB cells from unsorted
tumor spheres (C, F), CD133−/CD271+ cells (D, G), and CD133−/CD271− cells (E, H). Arrows in the upper panels depict highly infiltrative
MB cells and formation of smaller clusters of MB cells throughout the brain. The arrows in the lower panel denote intense perivascular
infiltration. Scale bars, 500 μm (upper panels), 100 μm (lower panels). (I–L) Parental DaoyMB tumor spheres (I) were sorted on the basis of
CD133/CD271 expression. Three subpopulations were sorted and recultured as tumor spheres for 6 days (J–L). Cultures derived from
sorted subpopulations were then evaluated for CD133/CD271 expression. Error bars, SEM.
Figure 7. CD271 levels are highest in fetal cerebellum and Shh MB and lower in more invasive and aggressive group 3 and group 4
molecular variants. (A) Data from Affymetrix exon array profiling of 14 normal cerebellar (9 fetal and 5 adult) samples (CB) and 111
primary MB presented as boxplots. CD271 expression is significantly higher in the fetal CB (***P < .001) and Shh subgroup (**P <
.01) relative to the more differentiated adult cerebellar samples and significantly lower in groups 3 (*P < .05) and 4 (**P < .01). Bars
denote 1.5 interquartile range within each group. (B) Working model depicting spectrum of cellular phenotypes and novel functional
relationships among cells expressing CD271 and CD133.
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These results demonstrate that there is an overall down-regulation of a
cell motility program in higher self-renewing MB tumor spheres and
that dysregulated Eph-ephrin signaling may be involved in MB TPC
function.
We have demonstrated differential expression of Eph-ephrin path-
way ligands and receptors in the higher versus lower self-renewing
tumor spheres; therefore, we also wanted to see whether this pathway
is also dysregulated in MB core versus migrating cells. We examined
transcript levels of the ephrin B2 ligand as well as the receptors
EPHB1, B2, B3, B4, and B6 by qPCR. We found that the ligand
ephrin B2 as well as the receptors EPHB1 and EPHB2 are signifi-
cantly upregulated in the migrating versus the core cells, while the
receptors EPHB3 and B4 are significantly downregulated (Figure W3,
A–F ). Together, our results demonstrate that the Eph-ephrin pathway
is not only differentially expressed in tumor spheres with variable self-
renewal capacity but also in migrating versus core MB cells. These data
suggest that the Eph-ephrin pathway may play an important functional
role in both MB TPCs and migration/invasion.
Discussion
In this study, we deconstructed MB cellular heterogeneity and iden-
tified a novel role for CD271 in enriching for a highly self-renewing
MB phenotype. We propose a dynamic model (Figure 7B) whereby a
highly self-renewing CD271↑, CD133↓ cell in the MB tumor core
may help sustain tumorigenesis. Once a cell commits its metabolic
machinery to migration and/or invasion, the levels of these cell sur-
face markers change, and a highly motile cell will acquire a CD271↓,
CD133↑ signature. As self-renewal and invasion are not mutually
exclusive, this concept aligns with recent studies demonstrating that
both CD133+ and CD133− cells exhibit BTPC function [8,9,11].
In addition, our work is also consistent with findings in glioblastoma
that reveal a spectrum of self-renewing and aggressive cellular pheno-
types that differentially express CD133 [12]. Highly self-renewing
and invasive cells have also been shown to proliferate less. Therefore,
it is not surprising that these subpopulations are distinct from those
exhibiting the highest cumulative cell count in our study. However,
it should be noted that the higher total cell number observed in
CD133/−CD271−MB cells might be attributed to a variety of mecha-
nisms including increased adhesion and/or survival upon replating of
sorted subpopulations combined with possible differences in cell cycle
properties. While we also observed some interesting trends with CD24,
this cell surface marker was in fact downregulated in stem cell condi-
tions relative to adherent cultures. This suggests that CD24 may mark
an MB progenitor population and is supported by expression patterns
during neural lineage specification where high levels of CD24 are
observed in transit-amplifying cells [32] and differentiated neurons
[33] and lower expression is seen in NSCs [34,35].
The inverse but not mutually exclusive correlation between self-
renewal and invasion is seemingly at odds with the positive relationship
between our most highly invasive MB subclones and their self-renewal
capacity depicted in Figure 2, A to C . These experiments were con-
ducted in bulk culture and did not determine whether those cells that
are invading are the same self-renewing TPCs that ultimately sustain
tumor sphere cultures. In fact, molecular characterization of the highly
self-renewing versus lower self-renewing tumor spheres from indepen-
dent subclones revealed a global down-regulation of the cell motility
transcription program in highly self-renewing tumor spheres. Even
though the higher self-renewing tumor spheres were derived from
adherent cultures exhibiting elevated invasion in collagen gel assays,
when placed in tumor sphere culture, the cell movement program is
downregulated. Therefore, changing the biologic context or micro-
environment also changes gene expression patterns representative of a
particular cell state. This is supported by our screening results demon-
strating CD271↑, CD133↓ in highly self-renewing tumor spheres but
CD271↓, CD133↑ in migrating cells. Indeed, these cell subpopula-
tions are not in a “static” state and can transition between phenotypes
to reestablish cellular heterogeneity. This concept was recently demon-
strated by Gupta et al. [15] with an elegant series of experiments using
breast cancer cell lines. Therefore, we cannot assume that a particular
set of cell surface markers will only select for one specific tumor cell
phenotype. Future studies will examine the epigenetic mechanisms that
may be responsible for the suppression of the cell motility program in
higher self-renewing MB tumor spheres.
CD271 is commonly referred to as p75 or p75NTR and is a mem-
ber of the tumor necrosis factor receptor family [36]. The receptor
normally functions in the development of the nervous system, includ-
ing growth cone elongation and axon guidance. CD271 has proapop-
totic and prosurvival effects, depending on the neurotrophin ligand
[36]. Recently, this receptor has also been linked to glioblastoma
Table 1. Dysregulation of Neural Developmental Pathway Transcripts in the Higher versus Lower Self-Renewing MB Tumor Spheres.
Entrez Gene Name Affymetrix/Entrez Gene/
Gene Symbol
Fold change (Higher versus
Lower Self-Renewing Tumor Spheres)
Myosin, light chain 1, alkali; skeletal, fast MYL1 4.2751
p21 protein (Cdc42/Rac)–activated kinase 3 PAK3 2.61359
Neurotrophic tyrosine kinase, receptor, type 2 NTRK2 2.44057
EPH receptor B1 EPHB1 2.16958
Myosin light chain, phosphorylatable, fast skeletal muscle MYLPF 2.14949
EPH receptor B3 EPHB3 2.11716
Dihydropyrimidinase-like 5 DPYSL5 2.06395
Tubulin, β4 TUBB4 2.02616
EPH receptor B6 EPHB6 −2.05668
Patched 2 PTCH2 −2.12875
Slit homolog 3 (Drosophila) SLIT3 −2.57108
Ephrin-B2 EFNB2 −2.69877
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C SEMA3C −2.8071
Sema domain, seven thrombospondin repeats (type 1 and type 1–like), transmembrane domain (TM)
and short cytoplasmic domain, (semaphorin) 5A
SEMA5A −3.1147
Eph-ephrin signaling transcripts are in bold.
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invasion [37] and could be targeted with the use of γ-secretase inhibi-
tors [38]. CD271 is also present in MB as well as the external granular
layer (EGL) and Purkinje layer in the developing human cerebellum
but absent in the adult cerebellum [39]. On the basis of expression
in both human fetal cerebellum and MB patient samples, the authors
suggested that CD271 could be a precursor marker linked with more
primitive cell populations [39]. Our primary patient MB and cerebellar
sample data revealed the same CD271 patterns. Interestingly, studies
have also demonstrated that CD271-positive cells in the EGL are
negative for CD133 [39]. This suggests that an inverse relationship
between these cell surface markers may also exist in the developing
cerebellum. It has been shown that granular neural precursors from
the cerebellar EGL are the cell of origin for the Shh-MB variant
[40,41]. The EGL is present in fetal but not adult cerebellum, and
therefore, it is not surprising that fetal cerebellar and Shh tumor
samples display high CD271 levels. CD271 may be important for
Shh-driven or desmoplastic MB tumors. Recent work has demon-
strated that CD271 is also involved with MB spinal metastasis [42].
While our study demonstrates that CD271+ cells do invade in vitro,
they do not exhibit the highest invasive capacity. Future studies will
explore the mechanisms responsible for the higher self-renewal capacity
seen in CD271+ cells as well as a potential link between CD271 and
Shh signaling in MB.
Another novel finding in our study was the differential expression
of genes related to axon guidance in MB tumor spheres and core versus
migrating cells. In particular, both ligands and receptors belonging to
the EphB–ephrin B pathway were differentially expressed inMB tumor
spheres as well as core versus migrating MB cells. Interestingly, global
gene expression analysis on higher versus lower self-renewing glioblas-
toma tumor spheres also revealed differential expression of the same
neurodevelopmental pathways, including six Eph-ephrin signaling
ligand and receptors (unpublished data). These data support our MB
findings and suggest that axon guidance pathways such as Eph-ephrin
signaling play a functional role in malignant brain tumor–initiating cell
or BTPC populations. The Eph-ephrin signaling pathways play impor-
tant roles in cellular communication and regulate a variety of aspects
during both normal development and disease progression including
adhesion, migration, invasion, cell proliferation, survival, and cell mor-
phology through reorganization of the actin cytoskeleton [43,44].
Notably, Eph-ephrin signaling has a well-established role in neuro-
development [44] and recent studies have even demonstrated that
ephrin signaling is regulated by CD271/p75NTR to control axon guid-
ance and mapping [45,46]. This raises the intriguing possibility that
Eph signaling and CD271 may be linked in MB as well. While studies
have shown that the Eph-ephrin pathway plays an important role in
glioma invasion [47–49] and most recently MB invasion in vitro
[50], to our knowledge, this is the first study to evaluate the Eph-ephrin
signaling expression profile in MB BTPC subpopulations. In fact, few
studies have examined the functional role of axon guidance pathways
specifically in MB [29]. These pathways may regulate the balance
betweenMB self-renewal and invasion. Recent findings in glioblastoma
lend support to this notion, as EphB2 signaling enhanced migration
and invasion while decreasing cell proliferation from cells in tumor
sphere culture [51].
In addition to Eph-ephrin signaling, our molecular profiling of
higher versus lower self-renewing tumor sphere subclones also revealed
differences in transcripts associated with the RhoGTPases such as p21
protein (Cdc42/Rac)–activated kinase 3. Although we did not spe-
cifically profile the sorted populations (i.e., CD133+/CD271− versus
CD133−/CD271−) or the invading cells in our collagen assays, it is
possible that the variation in cell motility patterns observed in these
gels may also be attributed to differences in axon guidance pathways
such as Eph-ephrin signaling and activation of RhoGTPases. Studies
are currently underway to evaluate the functional significance of
ephrin B–EphB signaling and the RhoGTPases in MB self-renewal
versus invasion using our model system.
Combinatory expression of CD271 and CD133 may serve as impor-
tant selective criteria for drug discovery that will enable concomitant
targeting of a spectrum of putative MB-propagating cells and the most
highly invasive cells that typically elude current therapies. We are
currently pursuing higher throughput flow cytometry technologies to
identify other potential cell surface markers that may also select for
these transitory phenotypes. This will be important as our studies sug-
gest that drugs targeting cells in the migratory or invasive state may not
abrogate the putative TPCs in a state of higher self-renewal.
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Figure W1. CD271 is enriched in tumor sphere culture and highly self-renewing MB subpopulations from multiple cell lines. (A, B) D283
parental adherent cultures grown in 10% FBS (left panels) do not express CD271 but exhibit high levels of CD133 expression by flow
cytometry. Following culture as tumor spheres in BTPC conditions, D283 begin to exhibit a small but consistent significant subpopulation
of CD271+ cells. CD133 expression is significantly decreased. Insets: live cell–only controls; N = 5 independent experiments. (C, D)
CD271 levels (C) are significantly higher in t-hENs relative to normal hENs. CD133 is unchanged t-hENs versus hENs (D); N = 3 inde-
pendent experiments.
Figure W2. Top diseases, molecular/cellular functions, and networks dysregulated in higher versus lower self-renewing MB tumor
spheres. (A) Top diseases (upper panel) and molecular and cellular functions (lower panel) dysregulated in higher self-renewing versus
lower self-renewing tumor spheres. (B) Top dysregulated cellular network consisting of molecules associated with cellular movement.
Note the presence of EPHB receptors and ephrin B2 ligand. Shaded green areas denote transcripts that are significantly downregulated
and red areas denote significantly upregulated transcripts in higher self-renewing versus lower self-renewing tumor spheres.
Figure W3. The Eph-ephrin signaling pathway is dysregulated in migrating versus core MB cells. (A–F) qPCR analysis of the ephrin B2
ligand and EPHB1, B2, B3, B4, and B6 receptors in “core” versus “migrating” Daoy MB cells. Note the up-regulation of ephrin B2,
EPHB1, and EPHB2 and significant down-regulation of EPHB3 and EPHB4 in “migrating” versus “core” cells. Error bars, SEM; *P <
.05, **P < .01, ***P < .001.
Table W4. Primer Sequences Used for qPCR Reactions.
Gene Forward Sequence Reverse Sequence Product (bp)
Ephrin B2 5′-GTT CGA CAA CAA GTC CCT TTG-3′ 5′-CTG AAG CAA TCC CTG CAA ATA-3′ 123
EPHB1 5′-GGA AAC GGG CTT ATA GCA AAG-3′ 5′-TCG TAA GTG AAG GGG TCA ATG-3′ 110
EPHB2 5′-GAC TCC ACT ACA GCG ACT GCT-3′ 5′-TCT CAT CGT AGC CAC TCA CCT-3′ 82
EPHB3 5′-TTG TCA ATA CCC TGG ACA AGC-3′ 5′-AAT CAC CAA CTG TCG TGA AGG-3′ 135
EPHB4 5′-AAT GTC ACC ACT GAC CGA GAG-3′ 5′-ATT TGA CCT CGT AGT CCA GCA-3′ 136
EPHB6 5′-AAT AGC CAC TTG GTG TGC AAG-3′ 5′-CAT GAG TAT CCC AAA GCT CCA-3′ 144
Otx2 5′-GAG GTG GCA CTG AAA ATC AAC-3′ 5′-TCT TCT TTT TGG CAG GTC TCA-3′ 136
Sox1 5′-TGG ATG AAG GAC AAA GAC CAG-3′ 5′-GTT TTG GTT CAG CGA TTG TGT-3′ 116
βIII tubulin 5′-GGC CTT TGG ACA TCT CTT CA-3′ 5′-TCG CAG TTT TCA CAC TCC TTC-3′ 147
